Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

SGMT

Sagimet Biosciences Inc

May 03 • 04:00PM ET

4.32

Dollar change -0.13
Percentage change -2.92	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO IWO IWC VTWG VTWV BTEC

Index	RUT	P/E	-	EPS (ttm)	-1.28	Insider Own	46.04%	Shs Outstand	21.38M	Perf Week	6.40%
Market Cap	137.89M	Forward P/E	-	EPS next Y	-3.73	Insider Trans	0.10%	Shs Float	17.22M	Perf Month	-20.73%
Income	-27.88M	PEG	-	EPS next Q	-0.39	Inst Own	37.92%	Short Float	12.01%	Perf Quarter	-57.01%
Sales	2.00M	P/S	68.95	EPS this Y	22.74%	Inst Trans	-	Short Ratio	2.10	Perf Half Y	21.69%
Book/sh	3.98	P/B	1.09	EPS next Y	-81.70%	ROA	-	Short Interest	2.07M	Perf Year	-
Cash/sh	2.97	P/C	1.45	EPS next 5Y	-	ROE	-	52W Range	2.13 - 20.71	Perf YTD	-20.30%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.23%	ROI	-30.61%	52W High	-79.14%	Beta	-
Dividend TTM	-	Quick Ratio	17.04	Sales past 5Y	0.00%	Gross Margin	94.85%	52W Low	102.82%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	17.04	EPS Y/Y TTM	-	Oper. Margin	-1537.00%	RSI (14)	45.56	Volatility	10.25% 7.52%
Employees	10	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-1393.80%	Recom	1.00	Target Price	40.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	12.87%	Payout	-	Rel Volume	0.78	Prev Close	4.45
Sales Surprise	-	EPS Surprise	33.63%	Sales Q/Q	-	Earnings	Mar 25 BMO	Avg Volume	985.71K	Price	4.32
SMA20	-2.98%	SMA50	-15.41%	SMA200	-43.53%	Trades		Volume	770,647	Change	-2.92%

Date	Action	Analyst	Rating Change	Price Target Change
May-02-24	Initiated	H.C. Wainwright	Buy	$32
Mar-25-24	Initiated	Leerink Partners	Outperform	$26
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Piper Sandler	Overweight	$67
Aug-08-23	Initiated	JMP Securities	Mkt Outperform	$30
Aug-08-23	Initiated	Goldman	Buy	$33

Apr-22-24 08:00AM	Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 (GlobeNewswire)
Mar-27-24 04:01PM	Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat (GlobeNewswire) +9.56%
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire) +15.74%
06:15AM	Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Feb-29-24 08:00AM	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
08:58PM	Loading…
Jan-25-24 08:58PM	Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock (GlobeNewswire) -13.62%
Jan-23-24 05:45PM	Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock (GlobeNewswire)
Jan-22-24 11:10PM	Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH (PR Newswire) +170.09%
07:00AM	Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH (GlobeNewswire)
Dec-04-23 08:00AM	Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic (GlobeNewswire) +7.12%
Nov-28-23 08:00AM	Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit (GlobeNewswire)
Nov-22-23 08:00AM	Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +13.58%
Nov-13-23 08:00AM	Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -13.73%
Nov-10-23 08:30AM	Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting 2023 (GlobeNewswire) -7.68%
Oct-24-23 11:00AM	Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting 2023 (GlobeNewswire)
04:05PM	Loading…
Oct-18-23 04:05PM	Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference (GlobeNewswire)
Sep-27-23 04:05PM	Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma (GlobeNewswire)
Aug-29-23 10:21AM	Load Up, Says Goldman Sachs About These 2 Strong Buy Stocks (TipRanks)
Aug-21-23 04:02PM	Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-15-23 04:04PM	Sagimet Biosciences Announces Closing of Underwriters Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering (GlobeNewswire)
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Jul-20-23 04:05PM	Sagimet Biosciences Announces Leadership Changes (GlobeNewswire)
Jul-13-23 09:10PM	Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Happel David	President & CEO	Mar 26 '24	Buy	5.27	12,100	63,731	639,200	Mar 28 04:08 PM
Happel David	President & CEO	Dec 07 '23	Buy	4.10	1,600	6,560	627,100	Dec 08 04:05 PM
Happel David	President & CEO	Nov 16 '23	Buy	2.35	590	1,386	590	Nov 20 09:59 PM
Kemble George	Executive Chairman	Sep 07 '23	Option Exercise	0.79	5,630	4,448	5,630	Sep 08 04:15 PM
SEIDENBERG BETH C	Director	Jul 18 '23	Buy	16.00	46,875	750,000	46,875	Jul 20 04:20 PM
NEW ENTERPRISE ASSOCIATES 13 L	10% Owner	Jul 18 '23	Buy	16.00	30,000	480,000	3,850,275	Jul 20 06:56 PM
NEW ENTERPRISE ASSOCIATES 13 L	10% Owner	Jul 18 '23	Sale	16.00	662	10,592	3,820,275	Jul 20 06:56 PM

Open in Screener

SLRN

Acelyrin Inc

May 03 • 04:00PM ET

4.35

Dollar change +0.10
Percentage change 2.35	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VBK IWM VXF IBB VTWO IWN IWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.92	Insider Own	37.98%	Shs Outstand	97.87M	Perf Week	2.59%
Market Cap	430.26M	Forward P/E	-	EPS next Y	-4.76	Insider Trans	-0.10%	Shs Float	61.35M	Perf Month	-31.92%
Income	-381.64M	PEG	-	EPS next Q	-0.96	Inst Own	72.80%	Short Float	12.79%	Perf Quarter	-45.90%
Sales	0.00M	P/S	-	EPS this Y	24.27%	Inst Trans	-	Short Ratio	6.30	Perf Half Y	-52.35%
Book/sh	6.71	P/B	0.65	EPS next Y	-15.86%	ROA	-	Short Interest	7.85M	Perf Year	-
Cash/sh	7.29	P/C	0.60	EPS next 5Y	-	ROE	-	52W Range	4.14 - 29.88	Perf YTD	-41.69%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-58.04%	52W High	-85.44%	Beta	2.45
Dividend TTM	-	Quick Ratio	8.65	Sales past 5Y	0.00%	Gross Margin	-	52W Low	5.07%	ATR (14)	0.34
Dividend Ex-Date	-	Current Ratio	8.65	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	26.41	Volatility	4.44% 6.03%
Employees	130	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	31.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-526.06%	Payout	-	Rel Volume	0.76	Prev Close	4.25
Sales Surprise	-	EPS Surprise	551.50%	Sales Q/Q	-	Earnings	May 13 AMC	Avg Volume	1.25M	Price	4.35
SMA20	-12.88%	SMA50	-34.06%	SMA200	-61.16%	Trades		Volume	946,404	Change	2.35%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-23	Initiated	Wells Fargo	Equal Weight	$11
Dec-08-23	Initiated	Citigroup	Neutral	$8
Sep-13-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Sep-05-23	Initiated	H.C. Wainwright	Buy	$44
May-30-23	Initiated	TD Cowen	Outperform
May-30-23	Initiated	Piper Sandler	Overweight	$68
May-30-23	Initiated	Morgan Stanley	Overweight
May-30-23	Initiated	Jefferies	Buy	$31

Apr-29-24 04:05PM	ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 (GlobeNewswire)
Mar-28-24 10:53PM	SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-27-24 04:01PM	Avalo Acquires Anti-IL-1 mAb and Announces Private Placement Financing of up to $185 Million (GlobeNewswire)
Mar-21-24 11:12AM	ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study (Zacks) -6.49%
07:00AM	Loading…
Mar-20-24 07:00AM	ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease (GlobeNewswire)
12:39AM	Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen (FierceBiotech.com)
Mar-11-24 10:04AM	After crushing loss last year, Acelyrin rebounds with psoriatic arthritis victory (FierceBiotech.com) +10.96%
08:02AM	ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients (GlobeNewswire)
Feb-15-24 04:05PM	ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications (GlobeNewswire)
Jan-10-24 11:30AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire) -5.08%
Jan-04-24 09:56AM	Final Deadline Approaching for Acelyrin, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of January 16, 2024 Lead Plaintiff Deadline (GlobeNewswire)
Jan-01-24 09:35AM	Acelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Dec-27-23 10:45AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire)
04:30PM	Loading…
Dec-20-23 04:30PM	ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors (GlobeNewswire) -5.94%
Dec-19-23 12:13AM	Robbins LLP Reminds Investors of Lawsuit Against Acelyrin, Inc. and Approaching Lead Plaintiff Deadline (GlobeNewswire)
Dec-18-23 04:14PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire) -7.49%
Dec-12-23 09:25PM	ACELYRIN, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2024 deadline (GlobeNewswire)
Dec-11-23 09:35AM	SLRN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire) -7.47%
Dec-04-23 03:00PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress - Hagens Berman (GlobeNewswire)
08:00AM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
Nov-30-23 04:30PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire) +5.66%
Nov-28-23 05:55PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2023 deadline (GlobeNewswire) -32.41%
01:44PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
Nov-27-23 09:09PM	Acelyrin blames CRO error for shocking phase 3 failure that sent shiver through biotech IPO market (FierceBiotech.com)
04:30PM	ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program (GlobeNewswire)
Nov-20-23 11:01AM	Acelyrin (SLRN) Faces Lawsuit after Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Nov-16-23 06:42PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
04:11PM	Loading…
04:11PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Nov-07-23 05:11PM	Acelyrin Inc (SLRN) Reports Q3 2023 Financial Results: Key Clinical Trials Progressing (GuruFocus.com)
04:05PM	ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Nov-06-23 07:00AM	ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer (GlobeNewswire)
Oct-31-23 04:30PM	ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023 (GlobeNewswire)
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Acelyrin, and Clorox and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-03-23 07:00AM	ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development (GlobeNewswire)
Sep-15-23 05:39PM	Why Acelyrin Stock Plummeted 59% This Week (Motley Fool)
Sep-11-23 04:05PM	ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa (GlobeNewswire)
Sep-06-23 07:00AM	ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-23 07:22PM	Billionaire Ken Griffin Pours Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks) +7.70%
Aug-14-23 04:05PM	ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Aug-07-23 04:30PM	ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023 (GlobeNewswire)
Jul-18-23 07:00AM	ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer (GlobeNewswire)
Jun-15-23 04:05PM	ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-09-23 04:10PM	ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
May-05-23 07:08PM	Drug Developer Acelyrin Raises $540 Million in IPO (The Wall Street Journal)

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lin Shao-Lee	Chief Executive Officer	Apr 01 '24	Sale	6.63	9,961	66,024	1,577,374	Apr 03 06:18 PM
Lin Shao-Lee	Chief Executive Officer	Feb 20 '24	Sale	7.60	15,701	119,403	1,587,335	Feb 22 07:04 PM
Lin Shao-Lee	Chief Executive Officer	Jan 02 '24	Sale	7.41	10,691	79,188	1,603,036	Jan 04 06:09 PM
Westlake BioPartners Fund II,	10% Owner	May 09 '23	Buy	18.00	1,250,000	22,500,000	9,790,729	May 11 09:16 PM
SEIDENBERG BETH C	Director	May 09 '23	Buy	18.00	1,250,000	22,500,000	9,790,729	May 11 09:13 PM
SEIDENBERG BETH C	Director	May 09 '23	Buy	18.00	60,000	1,080,000	60,000	May 11 09:13 PM
Gosebruch Henry O	Director	May 09 '23	Buy	18.00	50,000	900,000	50,000	May 11 09:06 PM
Svoronos Dawn	Director	May 09 '23	Buy	18.00	15,000	270,000	15,000	May 11 09:11 PM
Peloso Paul	Chief Medical Officer	May 09 '23	Buy	18.00	6,000	108,000	6,000	May 11 08:54 PM
Dier Mardi	CFO and CBO	May 09 '23	Buy	18.00	5,556	100,008	5,556	May 11 08:51 PM
Kim Mina	Chief Legal & Admin. Officer	May 09 '23	Buy	18.00	5,000	90,000	5,000	May 11 08:58 PM
Becker Daniel J.	Director	May 09 '23	Buy	18.00	3,000	54,000	3,000	May 11 09:02 PM
Dier Mardi	CFO and CBO	May 09 '23	Buy	18.00	1,750	31,500	875	May 11 08:51 PM
Oyston Ronald	Chief People Officer	May 09 '23	Buy	18.00	1,000	18,000	1,000	May 11 09:00 PM
Oyston Ronald	Chief People Officer	May 09 '23	Buy	18.00	26	468	26	May 11 09:00 PM

Open in Screener

VERA

Vera Therapeutics Inc

May 03 • 04:00PM ET

43.44

Dollar change -0.06
Percentage change -0.14	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

VERA Vera Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IBB SCHA DWAS IWN IWO VTWO LABU

Index	RUT	P/E	-	EPS (ttm)	-2.28	Insider Own	26.56%	Shs Outstand	44.45M	Perf Week	9.56%
Market Cap	2.33B	Forward P/E	-	EPS next Y	-2.33	Insider Trans	-11.47%	Shs Float	39.44M	Perf Month	16.12%
Income	-95.99M	PEG	-	EPS next Q	-0.53	Inst Own	63.58%	Short Float	16.01%	Perf Quarter	10.96%
Sales	0.00M	P/S	-	EPS this Y	3.08%	Inst Trans	1.76%	Short Ratio	5.87	Perf Half Y	297.44%
Book/sh	2.29	P/B	18.99	EPS next Y	-7.07%	ROA	-62.54%	Short Interest	6.31M	Perf Year	514.43%
Cash/sh	2.99	P/C	14.52	EPS next 5Y	-	ROE	-107.50%	52W Range	6.70 - 50.78	Perf YTD	182.44%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.22%	ROI	-62.76%	52W High	-14.45%	Beta	1.11
Dividend TTM	-	Quick Ratio	7.42	Sales past 5Y	0.00%	Gross Margin	-	52W Low	548.36%	ATR (14)	3.01
Dividend Ex-Date	-	Current Ratio	7.42	EPS Y/Y TTM	31.36%	Oper. Margin	0.00%	RSI (14)	55.25	Volatility	6.67% 8.05%
Employees	51	Debt/Eq	0.53	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	59.22
Option/Short	Yes / Yes	LT Debt/Eq	0.50	EPS Q/Q	50.54%	Payout	-	Rel Volume	0.54	Prev Close	43.50
Sales Surprise	-	EPS Surprise	-8.12%	Sales Q/Q	-	Earnings	Mar 20 BMO	Avg Volume	1.08M	Price	43.44
SMA20	5.60%	SMA50	1.29%	SMA200	78.88%	Trades		Volume	582,113	Change	-0.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-25-24	Initiated	Oppenheimer	Outperform	$26
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform	$29
Nov-10-23	Upgrade	Jefferies	Hold → Buy	$18 → $26
Aug-16-23	Initiated	Guggenheim	Buy	$27
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral	$33 → $8
Jan-04-23	Downgrade	Jefferies	Buy → Hold	$32 → $6
Jul-12-22	Initiated	JP Morgan	Overweight	$35
May-02-22	Initiated	H.C. Wainwright	Buy	$35
Apr-19-22	Initiated	Wedbush	Outperform	$32

Apr-23-24 05:09PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Apr-13-24 05:29AM	Could This Stock Be the Next Biotech Buyout? (Motley Fool)
Apr-12-24 07:01PM	Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ... (GuruFocus.com)
Apr-11-24 04:29PM	Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal (Yahoo Finance Video) +17.30%
Apr-05-24 06:30PM	ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors (Barrons.com)
08:00AM	Loading…
Apr-02-24 08:00AM	Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress (GlobeNewswire)
Mar-20-24 12:52PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:30AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-28-24 04:20PM	Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-02-24 12:40PM	Hedge Fund and Insider Trading News: Anthony Scaramucci, Ray Dalio, Ken Griffin, NWQ Capital Management, Man Group, Cleveland-Cliffs Inc (CLF), Vera Therapeutics, Inc. (VERA), and More (Insider Monkey)
08:00AM	Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Feb-01-24 04:05PM	Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Class A Common Stock (GlobeNewswire)
Jan-29-24 11:50PM	Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock (GlobeNewswire) +11.46%
06:15AM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Jan-25-24 06:30AM	Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy (GlobeNewswire) +48.71%
06:44PM	Loading…
Jan-12-24 06:44PM	Why Vera Therapeutics Stock Soared by 22% This Week (Motley Fool)
Jan-08-24 08:01AM	Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer (GlobeNewswire) +16.74%
08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024 (GlobeNewswire)
Dec-27-23 08:00AM	Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-15-23 10:15AM	This Promising Small-Cap Biotech Stock Could Rise 70%, According to Wall Street (Motley Fool) +8.70%
Nov-14-23 05:05PM	FMR LLC Adjusts Stake in Vera Therapeutics Inc (GuruFocus.com) +6.74%
09:55AM	Wall Street Analysts Believe Vera Therapeutics, Inc. (VERA) Could Rally 86.76%: Here's is How to Trade (Zacks)
Nov-09-23 09:29AM	Vera Therapeutics Inc (VERA) Reports Q3 Financial Results and Business Updates (GuruFocus.com)
08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results (GlobeNewswire)
Nov-04-23 10:00AM	Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023 (GlobeNewswire)
Oct-30-23 08:00AM	Vera Therapeutics Scheduled to Present at November Investor Conferences (GlobeNewswire) +8.32%
Oct-18-23 09:35AM	Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA) (Zacks) -5.09%
Oct-17-23 09:35AM	Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA) (Zacks)
Oct-16-23 09:35AM	Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a Turnaround (Zacks)
Oct-13-23 10:22AM	Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting (GlobeNewswire)
04:02PM	Loading…
Sep-26-23 04:02PM	Why Shares of Vera Therapeutics Jumped Tuesday (Motley Fool) +11.32%
Aug-31-23 08:00AM	Vera Therapeutics Scheduled to Present at September Investor Conferences (GlobeNewswire) -5.70%
Aug-16-23 10:00AM	Chevron upgraded, SolarEdge downgraded: Wall Street's top analyst calls (The Fly)
Aug-15-23 04:03PM	What Makes Vera Therapeutics, Inc. (VERA) a New Buy Stock (Zacks)
Aug-10-23 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results (GlobeNewswire) +6.22%
Aug-04-23 06:30PM	Apogee Therapeutics, Turnstone Biologics, and More Stocks See Action From Activist Investors (Barrons.com)
Jul-24-23 09:01AM	Positive Signs As Multiple Insiders Buy Vera Therapeutics Stock (Simply Wall St.) -6.82%
Jul-07-23 06:35PM	Masimo and Vera Therapeutics Stock See Action From Activist Investors (Barrons.com) +5.20%
Jun-27-23 08:05AM	Vera Therapeutics Likely Needs Time to Digest Its Recent Dramatic Gains (TheStreet.com)
Jun-20-23 07:04PM	Why Shares of Vera Therapeutics Jumped Tuesday (Motley Fool) +16.94%
09:33AM	2 Surging Healthcare Stocks With More Fuel in the Tank (Motley Fool)
Jun-17-23 10:10AM	Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress (GlobeNewswire)
Jun-15-23 04:44PM	Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN (GlobeNewswire)
Jun-12-23 12:05PM	Why Shares of Vera Therapeutics Are Soaring Monday (Motley Fool) +15.83%
Jun-11-23 01:08PM	7 Stocks That Wall Street Analysts Are Loving in June (InvestorPlace)
Jun-08-23 08:00AM	Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
Jun-07-23 08:00AM	Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN) (GlobeNewswire)
May-11-23 08:36AM	Should You Buy Vera Therapeutics (VERA) Ahead of Earnings? (Zacks)
07:30AM	Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results (GlobeNewswire)
May-04-23 08:00AM	Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs (GlobeNewswire)
Mar-28-23 07:30AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 04:05PM	Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-14-23 07:48AM	Chief Financial Officer Sean Grant Just Bought 207% More Shares In Vera Therapeutics, Inc. (NASDAQ:VERA) (Simply Wall St.)
Feb-09-23 06:51AM	Daily Vickers Top Buyers & Sellers for 02/09/2023 (Argus Research)
05:54AM	With 35% stake, Vera Therapeutics, Inc. (NASDAQ:VERA) seems to have captured institutional investors' interest (Simply Wall St.)
Feb-06-23 04:05PM	Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Class A Common Stock (GlobeNewswire)
Feb-01-23 09:52PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire)
04:01PM	Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock (GlobeNewswire)
Jan-30-23 07:35AM	Vera Therapeutics Releases Interim Analysis Of Rare Kidney Disease Drug, Deprioritizes Certain Phase 3 Programs (Benzinga) -6.06%
06:00AM	Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria (GlobeNewswire)
Jan-25-23 08:00AM	Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN) (GlobeNewswire)
Jan-22-23 07:39AM	Why Vera Therapeutics Stock Bolted Higher This Week (Motley Fool)
Jan-06-23 05:02AM	The Zacks Analyst Blog Highlights Geron, Chemomab Therapeutics, Phathom Pharmaceuticals, Vera Therapeutics and Novavax (Zacks)
Jan-04-23 04:07PM	Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update And Chinook Popped (Investor's Business Daily) -64.70%
12:20PM	VERA Dips Despite Positive Data From IgA Nephropathy Study (Zacks)
10:22AM	These 2 Nasdaq Biotechs Are Making Big Moves Wednesday (Motley Fool)
06:52AM	Vera Therapeutics Shares Plunge After Mixed Data From Rare Kidney Disease Study (Benzinga)
Jan-03-23 04:01PM	Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (GlobeNewswire) -5.43%
Dec-20-22 04:05PM	Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-25-22 07:38AM	One Vera Therapeutics, Inc. (NASDAQ:VERA) insider upped their stake by 329% in the previous year (Simply Wall St.)
Nov-22-22 07:30AM	Vera Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-17-22 07:30AM	Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP (GlobeNewswire)
Nov-09-22 07:30AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) -6.00%
Nov-05-22 04:50PM	Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney Week 2022 Annual Meeting (GlobeNewswire)
Oct-17-22 07:30AM	Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 2022 Annual Meeting (GlobeNewswire)
Sep-15-22 09:55AM	Wall Street Analysts Think Vera Therapeutics, Inc. (VERA) Could Surge 64%: Read This Before Placing a Bet (Zacks)
Sep-07-22 07:30AM	Vera Therapeutics to Present at Upcoming Conferences in September 2022 (GlobeNewswire) +5.93%
Aug-29-22 09:55AM	Wall Street Analysts See a 76% Upside in Vera Therapeutics, Inc. (VERA): Can the Stock Really Move This High? (Zacks) +11.10%
Aug-12-22 09:55AM	Can Vera Therapeutics, Inc. (VERA) Climb 79% to Reach the Level Wall Street Analysts Expect? (Zacks) +5.17%
Aug-10-22 07:30AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire) +9.03%
Aug-04-22 07:30AM	Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-06-22 07:30AM	Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (GlobeNewswire)
Jun-18-22 08:20AM	Insider Buying: The Vera Therapeutics, Inc. (NASDAQ:VERA) Chief Financial Officer Just Bought 329% More Shares (Simply Wall St.)
Jun-04-22 02:30PM	Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients (GlobeNewswire)
Jun-02-22 07:30AM	Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-20-22 04:05PM	Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress (GlobeNewswire)
May-16-22 07:30AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 04:05PM	Vera Therapeutics to Present at Upcoming Conferences in May 2022 (GlobeNewswire)
May-03-22 04:33PM	Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus (GlobeNewswire) -5.66%
May-02-22 07:06PM	Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022 (GlobeNewswire)
Apr-12-22 07:30AM	Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors (GlobeNewswire)
Mar-24-22 06:30AM	Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-21-22 07:30AM	Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher (GlobeNewswire) -7.30%
Mar-17-22 07:30AM	Vera Therapeutics to Host Business Update Call (GlobeNewswire)
Mar-01-22 07:30AM	Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-22-22 05:29AM	We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth (Simply Wall St.)
Feb-14-22 04:01PM	Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-10-22 08:46AM	Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock (GlobeNewswire) -6.56%
Feb-07-22 05:24PM	Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock (GlobeNewswire) +7.72%
Jan-18-22 07:30AM	Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis (GlobeNewswire)

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Apr 10 '24	Sale	40.00	5,714	228,560	53,171	Apr 12 04:02 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Option Exercise	14.87	99,828	1,484,442	166,165	Apr 05 09:32 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	39.61	99,828	3,954,516	66,337	Apr 05 09:32 PM
Grant Sean	CHIEF FINANCIAL OFFICER	Apr 03 '24	Sale	39.42	18,649	735,205	0	Apr 05 09:32 PM
Katabi Maha	Director	Mar 25 '24	Sale	40.50	340,000	13,770,000	2,793,987	Mar 25 09:46 PM
Katabi Maha	Director	Mar 22 '24	Sale	40.51	413,450	16,748,860	3,133,987	Mar 25 09:46 PM
Katabi Maha	Director	Mar 21 '24	Sale	44.20	81,009	3,580,723	3,547,437	Mar 25 09:46 PM
Katabi Maha	Director	Jan 30 '24	Buy	31.00	161,290	4,999,990	3,628,446	Feb 01 05:58 PM
COMMODORE CAPITAL LP	10% Owner	Jan 10 '24	Sale	18.00	1,050,000	18,900,000	4,400,000	Jan 12 09:55 PM
Fordyce Marshall	President and CEO	Dec 29 '23	Option Exercise	2.87	13,516	38,854	256,877	Jan 03 04:15 PM
Fordyce Marshall	President and CEO	Aug 21 '23	Sale	16.66	5,210	86,779	243,361	Aug 23 05:56 PM
Curley Joanne	Chief Development Officer	Aug 21 '23	Sale	16.66	1,490	24,817	26,962	Aug 23 05:57 PM
Lin Celia	Chief Medical Officer	Aug 21 '23	Sale	16.65	1,490	24,816	11,010	Aug 23 05:59 PM
Young Joseph R	SVP, Finance, Chief Acct Offcr	Jul 05 '23	Option Exercise	3.94	10,000	39,396	32,679	Jul 06 04:05 PM
Grant Sean	Chief Financial Officer	Jun 23 '23	Buy	16.60	5,000	83,000	5,992	Jun 23 04:05 PM
COMMODORE CAPITAL LP	10% Owner	Jun 20 '23	Buy	15.17	448,217	6,799,004	5,450,000	Jun 22 04:10 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

SGMT

Sagimet Biosciences Inc

SLRN

Acelyrin Inc

VERA

Vera Therapeutics Inc

Upgrade your FINVIZ experience